Will NIH Learn from Myriad when Settling Its mRNA Inventorship Dispute with Moderna?
The NIH, which funded much of Moderna’s research on the COVID-19 vaccine, should be assertive in exerting control over the results of this research.
Gene Patents
-
Read more: Will NIH Learn from Myriad when Settling Its mRNA Inventorship Dispute with Moderna? -
Read more: The Civil Rights Challenge to Gene Patenting The Civil Rights Challenge to Gene Patenting
The ACLU mounted an unprecedented challenge the entire practice of gene patenting in America. And, against the odds, they won.
-
Read more: What Ever Happened to NIH’s “Fair Pricing” Clause? What Ever Happened to NIH’s “Fair Pricing” Clause?
It remains to be seen whether Congress or the Administration adopt more decisive measures toward the control of drug prices than they have in the past.
-
Read more: Contracting to counter gene patents – a 21st Century solution to access and innovation Contracting to counter gene patents – a 21st Century solution to access and innovation
By Sarah Ali-Khan and E. Richard Gold As Precision Medicine becomes a reality, molecular tests are an increasingly critical part of patient care. While patients and their physicians would like to maximize access, they have confronted a roadblock in the form of patents covering genes and methods of diagnosis. Many hoped that the landmark 2013…
-
Read more: Art Caplan on the Myriad Decision: Patenting natural DNA never made sense Art Caplan on the Myriad Decision: Patenting natural DNA never made sense
By Arthur Caplan Bill of Health contributor Art Caplan weighed in on the Supreme Court’s decision in the Myriad case with an opinion piece at NBC: “The Supreme Court has finally done what should have been done years ago — declared that genes which naturally exist in all of us cannot be patented. For years…